HSDD | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

84 results for “HSDD”

Trials

View all 49 →

Flibanserin Versus Placebo in Premenopausal Women With HSDD

945 participants · First posted Jun 26, 2007

Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)

653 participants · First posted Sep 19, 2017

Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)

24 participants · First posted Aug 25, 2010

Drugs

View all 26 →

Flibanserin(Addyi)

Conditions: Hypoactive Sexual Desire Disorder (HSDD)

C₂₀H₂₁F₃N₄O · Rx

hSDF-154

HSD-1933

News

Acrux Advances Female Testosterone Therapy to Phase III for HSDD Treatment

FDA Grants Priority Review for Flibanserin Expansion to Postmenopausal Women with HSDD

FDA Approves Expanded Flibanserin Indication for Postmenopausal Women with Hypoactive Sexual Desire Disorder

Page 1 of 9